(Reuters) -French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio ...

Sanofi agreed to buy UK vaccine developer Vicebio Ltd. for as much as $1.6 billion, as it seeks to expand in respiratory ...

Vicebio, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, has ...

The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

Sanofi has signed an agreement to acquire UK-based biotechnology company Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities. The deal also includes additional ...

French pharmaceutical and healthcare company Sanofi has agreed to buy the British biotechnology firm Vicebio for up to $1.6bn ...

Sanofi said on Tuesday it has agreed to acquire Vicebio, a privately held biotechnology company based in London, in a deal ...

Vicebio Ltd, a biopharmaceutical company developing novel vaccines, has entered an exclusive, definitive agreement to be ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Paris-based drugmaker Sanofi is acquiring U,K,-based Vicebio to gain its molecular clamp vaccine technology, with the total ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...